View Post

IACS and other platforms develop new cancer treatments for clinical trials

In Clinical Trials by Barbara Jacoby

By: Clayton R. Boldt, Ph.D. From: mdanderson.org Therapeutics Discovery scientists bring clinical cancer research to the lab and use unique model for drug development to benefit cancer patients. “From the bench to the bedside” is a phrase often used to describe a drug discovery’s journey from the laboratory to the clinic, where patients benefit. MD Anderson’s Therapeutics Discovery division, however, …

View Post

EnGeneIC Announces First Patients with Advanced-Stage Pancreatic Cancer Dosed in Phase 1/2a Clinical Study of Targeted Cytotoxic Immunotherapy

In Clinical Trials by Barbara Jacoby

Source: EnGeneIC Limited From: prnewswire.com EnGeneIC Limited, a clinical-stage biopharmaceutical company advancing its proprietary EDV™ nanocell platform for targeted cyto-immunotherapy in cancer, today announced that the first four patients have been dosed in a Phase 1/2a study using the Company’s tumor-targeting, immunogenic EDVs™ to deliver a cytotoxic drug payload directly to tumors of patients who have exhausted curative treatment options. The …

View Post

Roswell Park Comprehensive Cancer Center Selects Circuit Clinical™ as a Collaborator for Groundbreaking CIMAvax Clinical Trial

In Clinical Trials by Barbara Jacoby

From: prnewswire.com Circuit Clinical™ is proud to announce a unique collaboration with Roswell Park Comprehensive Cancer Center, to support the expansion of clinical trial opportunities to its outpatient oncology practices.  This collaboration marks Circuit Clinical’s entry into oncology clinical research, with both digital and clinical services. Circuit Clinical will be delivering both research operational support and TrialScout™ – its patient experience platform – in …

View Post

Perlmutter Cancer Center Expands Clinical Trials Program

In Clinical Trials by Barbara Jacoby

From: nyulangone.org Over the last five years, Perlmutter Cancer Center’s Clinical Trials Office (CTO) has tripled in size. With shortened opening times, expanded biobanking, a budding phase I clinical trials drug development program, new metric-tracking tools, and increased patient accrual across a growing clinical network, the CTO team has steadily grown and strengthened its relationships with pharmaceutical and biotech companies— …

View Post

Q&A: Epigenetic Therapies for Breast Cancer

In Clinical Trials by Barbara Jacoby

By: Katarina Zimmer From: the-scientist.com Nancy Davidson is the senior vice president and director of the Clinical Research Division at Fred Hutchinson Cancer Research Center, and has been studying the molecular mechanisms that drive breast cancer for the past three decades. In recent years, her lab has investigated the role of epigenetic changes that occur during the disease, and whether …

View Post

Propanc Biopharma Initiates Development of Bio-Analytical Assay in Preparation for Human Trials

In Clinical Trials by Barbara Jacoby

From: prnewswire.com Feasibility Study Intends to Quantify PRP’s Active Ingredients in Human Serum Propanc Biopharma, Inc. (OTCQB: PPCB) (“Propanc”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that it has initiated development of a bio-analytical assay intended to quantify the active ingredients of the company’s lead product candidate, PRP, in preparation …

View Post

Intraoperative radiotherapy viable for certain patients with breast cancer

In Clinical Trials by Barbara Jacoby

By: Jennifer Southall From: healio.com Intraoperative radiotherapy remains a viable option for patients with low-risk breast cancer, according to a presenter at Miami Breast Cancer Conference. “Intraoperative radiotherapy has been used for at least 10 to 15 years and, in appropriately selected patients, published results of the treatment are quite good,” Frank A. Vicini, MD, FACR, FABS, FASTRO, radiation oncologist …

View Post

FDA suggests letting more patients with viral infections into cancer clinical trials

In Clinical Trials by Barbara Jacoby

By: Alaric DeArment From: medcitynews.com A draft guidance, not yet implemented, suggests allowing more patients with hepatitis B and C and HIV into oncology clinical trials from which they are currently excluded. On the pages of oncology clinical trials on the database ClinicalTrials.gov, the section listing the various criteria that patients must meet for enrollment commonly includes a line stating …

View Post

Should Patients Have to Pay for the Drugs They Helped Test?

In Clinical Trials by Barbara Jacoby

By: Len Lichtenfeld, M.D. From: curetoday.com Here is an interesting situation that I learned about recently, and it has me asking a question I hadn’t thought of before: What is our obligation to those who participated in and benefited from clinical trials but then are charged huge copays to continue taking the drugs they helped develop when the medi­cines get …

View Post

U of S ‘assassin antibody’ shows promise in killing cancer

In Clinical Trials by Barbara Jacoby

By: Chris Vandenbreekel From: .cjme.com A promising research breakthrough at the University of Saskatchewan could end up being a cure for colorectal cancer. A research team has developed an “assassin antibody” that attaches itself to colorectal cancer cells and destroys them with an astonishing success rate. “We’ve had up to 80 per cent of animals completely disease free,” research lead …